Share price · EOCN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when EOCN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 19 Aug 2026+751.5%
- 1 Jul 2026+16.4%
Nothing announced by EOCN that day or the session before.
- 11 Jun 2026+17.3%
Nothing announced by EOCN that day or the session before.
- 8 Jun 2026-32.6%
- 9 Apr 2026+26.2%
- 27 Mar 2026-14.2%
Nothing announced by EOCN that day or the session before.
- 25 Feb 2026+15.1%
Nothing announced by EOCN that day or the session before.
- 10 Dec 2025-8.6%
Nothing announced by EOCN that day or the session before.
- 3 Dec 2025+11.6%
Nothing announced by EOCN that day or the session before.
- 26 Nov 2025+12.4%
Share of unusual movement by asset
For each asset, the share of EOCN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Stearoyl-CoA desaturase 1 (SCD1) | MASH / NASH |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
Financial reports
Quarterly & interim (7)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $1.8M | $2.9M+ $5.9M short-term inv. | $2.7M | report ↗ |
View 6 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | — | $1.1M | $3.3M+ $8.2M short-term inv. | $1.9M-$1.9M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.1M | $5.0M+ $8.1M short-term inv. | $2.5M | report ↗ |
| 2024-Q3 | — | $0.7M | — | $1.9M-$1.1M operating cash flow | report ↗ |
| 2024-Q2 | — | $0.5M | $1.8M+ $5.9M short-term inv. | $1.1M | report ↗ |
| 2023-Q2 | — | $0.8M | $1.0M+ $7.6M short-term inv. | $1.6M | report ↗ |
| 2022-Q2 | — | $2.6M | $2.0M+ $20M short-term inv. | $3.7M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $4.9M | $4.0M+ $7.0M short-term inv. | $2.6M-$6.3M operating cash flow | report ↗ |
Galmed Pharmaceuticals did not disclose revenue for fiscal year 2025. R&D spend was $4.87M, up 63.4% YoY, with cash and equivalents of $3.99M. The company reported a net loss of $10.31M and a quarterly net burn of $10.31M.
The company is advancing Aramchol for oncological indications outside NASH and fibrosis and is evaluating cardiometabolic and other innovative product candidates. It discontinued the open-label part of the ARMOR Study and does not currently expect to initiate the second part; management also noted substantial doubt about the company’s ability to continue as a going concern, while estimating that current cash supports operations for more than 12 months.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $3.0M | $4.7M+ $7.2M short-term inv. | $1.9M-$5.9M operating cash flow | report ↗ |
| 2023-FY | — | $3.6M | $2.9M+ $7.5M short-term inv. | $1.7M-$6.1M operating cash flow | report ↗ |
| 2022-FY | — | $13M | $2.0M+ $12M short-term inv. | $4.5M-$19M operating cash flow | report ↗ |
| 2021-FY | — | $27M | $2.9M+ $32M short-term inv. | $8.1M-$33M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
No Form 4 transactions on file in the stored window.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 16 reporting institutions held 0.1M shares ($71K).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | 80,177 | $39K |
| 2 | XTX Topco Ltd | 22,396 | $11K |
| 3 | JANE STREET GROUP, LLC | 16,445 | $8K |
| 4 | TWO SIGMA SECURITIES, LLC | 11,971 | $6K |
| 5 | CITADEL ADVISORS LLC | 11,382 | $6K |
| 6 | UBS Group AG | 2,546 | $1K |
| 7 | BNP PARIBAS FINANCIAL MARKETS | 600 | $294 |
| 8 | MORGAN STANLEY | 157 | $77 |
| 9 | WELLS FARGO & COMPANY/MN | 43 | $21 |
| 10 | SBI Securities Co., Ltd. | 16 | $8 |
| 11 | Federation des caisses Desjardins du Quebec | 14 | $7 |
| 12 | OSAIC HOLDINGS, INC. | 5 | $2 |
| 13 | Allworth Financial LP | 2 | $1 |
| 14 | ELEVATION WEALTH PARTNERS, LLC | 1 | $1 |
| 15 | Dogwood Wealth Management LLC | 1 | $0 |